Patents by Inventor Russ Lehrman

Russ Lehrman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190316186
    Abstract: A method and system for classifying a target nucleic acid includes exposing, in a test system, one or more capture probes to the target nucleic acid. The one or more capture probes is attached to a surface. A first hybridization condition is established in the test system. A first degree of hybridization of the one or more capture probes with the target nucleic acid under the first hybridization condition is determined. A second hybridization condition in the test system is established. A second degree of hybridization of the one or more capture probes with the target nucleic acid under the second hybridization condition is determined and the target nucleic acid is classified by comparing the first and the second degrees of hybridization.
    Type: Application
    Filed: May 1, 2019
    Publication date: October 17, 2019
    Inventors: David Lawrence Medin, Sherwood Russ Lehrman
  • Publication number: 20180194843
    Abstract: A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, polysorbate 80, a buffer which inhibits polysorbate oxidation is described along with methods of making the preparation. Also described are formulations with high antibody concentrations which maintain fixed volumes and which may be used on patients of variable weight.
    Type: Application
    Filed: March 7, 2018
    Publication date: July 12, 2018
    Inventors: David J. Burke, Shaun E. Buckley, Sherwood Russ Lehrman, Barbara Horsey O'Connor, James Callaway, Christopher P. Phillips
  • Publication number: 20180057865
    Abstract: A method and system for classifying a target nucleic acid includes exposing, in a test system, one or more capture probes to the target nucleic acid. The one or more capture probes is attached to a surface. A first hybridization condition is established in the test system. A first degree of hybridization of the one or more capture probes with the target nucleic acid under the first hybridization condition is determined. A second hybridization condition in the test system is established. A second degree of hybridization of the one or more capture probes with the target nucleic acid under the second hybridization condition is determined and the target nucleic acid is classified by comparing the first and the second degrees of hybridization.
    Type: Application
    Filed: May 3, 2017
    Publication date: March 1, 2018
    Inventors: David Lawrence Medin, Sherwood Russ Lehrman
  • Publication number: 20150044206
    Abstract: A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, polysorbate 80, a buffer which inhibits polysorbate oxidation is described along with methods of making the preparation. Also described are formulations with high antibody concentrations which maintain fixed volumes and which may be used on patients of variable weight.
    Type: Application
    Filed: October 27, 2014
    Publication date: February 12, 2015
    Applicant: BIOGEN IDEC MA INC.
    Inventors: David J. BURKE, Shaun E. BUCKLEY, Sherwood Russ LEHRMAN, Barbara Horsey O'CONNOR, James CALLAWAY, Christopher P. PHILLIPS
  • Patent number: 8900577
    Abstract: A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, polysorbate 80, a buffer which inhibits polysorbate oxidation is described along with methods of making the preparation. Also described are formulations with high antibody concentrations which maintain fixed volumes and which may be used on patients of variable weight.
    Type: Grant
    Filed: September 6, 2012
    Date of Patent: December 2, 2014
    Assignee: Biogen Idec Ma Inc.
    Inventors: David J. Burke, Shaun E. Buckley, Sherwood Russ Lehrman, Barbara Horsey O'Connor, James Callaway, Christopher P. Phillips
  • Patent number: 8815236
    Abstract: A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, polysorbate 80, a buffer which inhibits polysorbate oxidation is described along with methods of making the preparation. Also described are formulations with high antibody concentrations which maintain fixed volumes and which may be used on patients of variable weight.
    Type: Grant
    Filed: November 14, 2012
    Date of Patent: August 26, 2014
    Assignee: Biogen Idec MA Inc.
    Inventors: David J. Burke, Shaun E. Buckley, Sherwood Russ Lehrman, Barbara Horsey O'Connor, James Callaway, Christopher P. Phillips
  • Publication number: 20140051596
    Abstract: A method and system for classifying a target nucleic acid includes exposing, in a test system, one or more capture probes to the target nucleic acid. The one or more capture probes is attached to a surface. A first hybridization condition is established in the test system. A first degree of hybridization of the one or more capture probes with the target nucleic acid under the first hybridization condition is determined. A second hybridization condition in the test system is established. A second degree of hybridization of the one or more capture probes with the target nucleic acid under the second hybridization condition is determined and the target nucleic acid is classified by comparing the first and the second degrees of hybridization.
    Type: Application
    Filed: August 16, 2013
    Publication date: February 20, 2014
    Applicant: Bio-NEMS Corporation
    Inventors: David Lawrence Medin, Sherwood Russ Lehrman
  • Patent number: 8349321
    Abstract: A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, polysorbate 80, a buffer which inhibits polysorbate oxidation is described along with methods of making the preparation. Also described are formulations with high antibody concentrations which maintain fixed volumes and which may be used on patients of variable weight.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: January 8, 2013
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: David J. Burke, Shaun E. Buckley, Sherwood Russ Lehrman, Barbara Horsey O'Connor, James Callaway, Christopher P. Phillips
  • Publication number: 20120328614
    Abstract: A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, polysorbate 80, a buffer which inhibits polysorbate oxidation is described along with methods of making the preparation. Also described are formulations with high antibody concentrations which maintain fixed volumes and which may be used on patients of variable weight.
    Type: Application
    Filed: September 6, 2012
    Publication date: December 27, 2012
    Applicant: Elan Pharmaceuticals, Inc.
    Inventors: David J. Burke, Shaun E. Buckley, Sherwood Russ Lehrman, Barbara Horsey O'Connor, James Callaway, Christopher P. Phillips
  • Publication number: 20100021461
    Abstract: A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of an antibody, polysorbate 80, a buffer which inhibits polysorbate oxidation is described along with methods of making the preparation. Also described are formulations with high antibody concentrations which maintain fixed volumes and which may be used on patients of variable weight.
    Type: Application
    Filed: October 2, 2009
    Publication date: January 28, 2010
    Applicant: Elan Pharmaceuticals, Inc.
    Inventors: David J. BURKE, Shaun E. Buckley, Sherwood Russ Lehrman, Barbara Horsey O'Connor, James Callaway
  • Patent number: 6838075
    Abstract: The present invention provides highly dispersible spray-dried powder compositions, and in particular, inhaleable dry powder compositions for aerosolized delivery to the lungs. The powders of the invention are produced by spray drying a 4 ?-helix bundle protein under conditions which both (i) protect the protein from aggregation and (ii) provide particles suitable for inhalation (i.e., demonstrating superior aerosol performance).
    Type: Grant
    Filed: March 14, 2003
    Date of Patent: January 4, 2005
    Assignee: Nektar Therapeutics
    Inventors: Cynthia Stevenson, Jayne E. Hastedt, Russ Lehrman, Hi-Shi Chiang, David B. Bennett, David Lesikar, Bing Yang, David Gong, Kirsten Cabot
  • Publication number: 20030190291
    Abstract: The present invention provides highly dispersible spray-dried powder compositions, and in particular, inhaleable dry powder compositions for aerosolized delivery to the lungs. The powders of the invention are produced by spray drying a 4 &agr;-helix bundle protein under conditions which both (i) protect the protein from aggregation and (ii) provide particles suitable for inhalation (i.e., demonstrating superior aerosol performance).
    Type: Application
    Filed: March 14, 2003
    Publication date: October 9, 2003
    Applicant: Nektar Therapeutics
    Inventors: Cynthia Stevenson, Jayne E. Hastedt, S. Russ Lehrman, Hi-Shi Chiang, David B. Bennett, David Lesikar, Bing Yang, David Gong, Kirsten Cabot
  • Patent number: 6569406
    Abstract: The present invention provides highly dispersible spray-dried powder compositions, and in particular, inhaleable dry powder compositions for aerosolized delivery to the lungs. The powders of the invention are produced by spray drying a 4 &agr;-helix bundle protein under conditions which both (i) protect the protein from aggregation and (ii) provide particles suitable for inhalation (i.e., demonstrating superior aerosol performance).
    Type: Grant
    Filed: August 7, 2001
    Date of Patent: May 27, 2003
    Assignee: Nektar Therapeutics
    Inventors: Cynthia Stevenson, Jayne E. Hastedt, S. Russ Lehrman, Hi-Shi Chiang, David B. Bennett, David Lesikar, Bing Yang, David Gong, Kirsten Cabot
  • Publication number: 20020065399
    Abstract: The present invention provides highly dispersible spray-dried powder compositions, and in particular, inhaleable dry powder compositions for aerosolized delivery to the lungs. The powders of the invention are produced by spray drying a 4 &agr;-helix bundle protein under conditions which both (i) protect the protein from aggregation and (ii) provide particles suitable for inhalation (i.e., demonstrating superior aerosol performance).
    Type: Application
    Filed: August 7, 2001
    Publication date: May 30, 2002
    Applicant: Inhale Therapeutic Systems, Inc.
    Inventors: Cynthia Stevenson, Jayne E. Hastedt, S. Russ Lehrman, Hi-Shi Chiang, David B. Bennett, David Lesikar, Bing Yang, David Gong, Kirsten Cabot
  • Patent number: 5663305
    Abstract: The present invention provides analogs of animal somatotropins particularly with changes in the amino acids between residue 96 to 133 which are changed to reduce hydrophobicity or helical stability.
    Type: Grant
    Filed: December 29, 1994
    Date of Patent: September 2, 1997
    Assignee: The Upjohn Company
    Inventors: Sherwood Russ Lehrman, Henry A. Havel, Jody L. Tuls, Scott M. Plaisted, David N. Brems